Scientific interests:
Clinical trials and drug development in psychiatry
Academic Education:
1998 to 2004
Study of Pharmacy, Rheinische Friedrich-Wilhelms-University Bonn, Germany
2008 to 2015
Postgraduate student at the University of Cologne, Cologne, Germany
Doctoral thesis (Ph.D.):
2015
Dr. rer. medic. (rerum medicinalium) / Doctor of Biomedicine:
„Exploration of endocannabinoids and related fatty acide ethanolamides in serum of patients suffering Borderline Personality Disorders and/or Posttraumatic Stress Disorders: Validation of a LC-MS/MS method.“, University of Cologne, Germany
Professional activity:
2006 to 2009
Postgraduate student, Dept. of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany
Research group Experimental and Clinical Neuropsychopharmacology
Research group Experimental and Clinical Neuropsychopharmacology
2006 to 2012
Pharmacist at the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte), Bonn, Germany (part time)
2009 to 2015
Postgraduate student, Dept. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
RG Translational Research in Psychiatry
RG Translational Research in Psychiatry
2015
Post doc, Dept. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
2016 to 2018
Project Manager, Centre for Clinical Trials, Bonn University, Bonn, Germany
2018 to 2021
Maternal leave
2021 to current
Project Manager, Endosane Pharmaceuticals GmbH, Berlin, Germany
2021 to current
Associated Research Fellow, Central Institute of Mental Health Mannheim, Germany
Publications:
ORCID iD:
https://orcid.org/0000-0002-3826-2220- T. A. Couttas, C. Boost, F. Pahlisch, E. B. Sykorova, D. Koethe, J. E. Leweke, H. Endepols, C. Rohleder, F. M. Leweke (2022) Simultaneous assessment of serum levels and pharmacologic effects of cannabinoids on endocannabinoids and N-acylethanolamines by liquid chromatography – tandem mass spectrometry. Cannabis Cannabinoid Res 2022, 6:657-669
- Y. Bouter, M. M. Brzózka, R. Rygula, F. Pahlisch, C. Boost, F. M. Leweke, U. Havemann-Reinecke*, C. Rohleder* (2019) Chronic psychosocial stress causes increased anxiety-like behavior and alters endocannabinoid levels in the brain in C57Bl/6J mice. Cannabis Cannabinoid Res 5:51-61
- M. Schneider, F. Kasanetz, D. L. Lynch, C. M. Friemel, O. Lasalle, D. P. Hurst, F. Steindel, K. Monory, C. Schaefer, I. Miederer, F. M. Leweke, M. Schreckenberger, B. Lutz, P. H. Reggio, O. J. Manzoni, R. Spanagel (2015) Enhanced functional activity of the cannabinoid type-1 receptor mediate adolescent behavior. J Neurosci 31: 13975–88
- M. Grosshans, E. Schwarz, J. M. Bumb, C. Schaefer, C. Rohleder, C. Vollmert, S. Vollstadt-Klein, H. Tost, A. Meyer-Lindenberg, F. Kiefer, F. M. Leweke (2014) Oleoylethanolamide and human neural responses to food stimuli in obesity. JAMA Psychiatry 71, 1254-61.
- C. Schaefer, F. Enning, J. K. Mueller, J. M. Bumb, C. Rohleder, T. M. Odorfer, J. Klosterkotter, M. Hellmich, D. Koethe, C. Schmahl, M. Bohus, F. M. Leweke (2014) Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. Eur Arch Psychiatry Clin Neurosci 264:459-463.
- C. J. Morgan, E. Page, C. Schaefer, K. Chatten, A. Manocha, S. Gulati, H. V. Curran, B. Brandner, F. M. Leweke (2013) Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br J Psychiatry 202:381-382